Amgen Inc. stock (US0311621009): Shares steadier as S&P 500 biotech name trades around recent range

Amgen stock on Nasdaq traded roughly in line with the broader US market on 05/28/2026, as investors weighed recent obesity pipeline updates and upcoming data milestones for the large-cap biotechnology group.

Amgen stock on the Nasdaq Global Select Market traded broadly in line with the wider US equities market on 05/28/2026, with investors continuing to focus on the group’s position in obesity treatments and its role as a major biotechnology constituent of the S&P 500 in the United States, according to Nasdaq pricing data as of 05/28/2026.

The shares, which trade under the ticker AMGN and are part of the large-cap US healthcare universe, have been oscillating in a relatively tight range in recent sessions as the market digests earlier updates on the company’s weight-loss candidate AMG 133 and tracks sector flows into and out of blue-chip biotech names, based on Nasdaq and US market data as of 05/28/2026.

As of: 05/28/2026

By the editorial team - specialized in equity coverage.

At a glance

• Name: Amgen Inc.
• Sector/industry: Biotechnology and biopharmaceuticals
• Headquarters/country: Thousand Oaks, United States
• Core markets: United States, Europe, and other international pharmaceutical markets
• Key revenue drivers: Innovative biologic therapies in oncology, inflammation, bone health and cardiovascular disease, complemented by biosimilars and a late-stage pipeline
• Home exchange/listing venue: Nasdaq Global Select Market (AMGN)
• Trading currency: USD

Amgen Inc.: core business model

Amgen operates as a global biotechnology company that discovers, develops, manufactures, and commercializes human therapeutics, with sales driven largely by a portfolio of established biologic drugs and biosimilars alongside a pipeline that includes next-generation cardiometabolic and inflammation candidates such as obesity-focused AMG 133.

Industry trends and competitive position

Within the global pharmaceuticals and biotechnology industry, Amgen is viewed as one of the larger diversified players in the United States biotech landscape, competing for capital with European and US peers that are also investing heavily in specialty therapies and biologics. The broader sector continues to see strong interest in drugs targeting chronic diseases such as obesity and cardiovascular conditions, a field in which large-cap names like Novo Nordisk and Eli Lilly currently hold meaningful positions through their GLP-1 and related weight-loss portfolios, while other companies, including Amgen, are trying to carve out differentiated approaches through pipeline assets focused on similar patient populations based on industry commentary and company disclosures in 2025 and 2026.

According to sector studies and healthcare data providers in 2025, the obesity treatment market is projected to expand significantly over the coming years as payers, physicians, and patients increasingly seek pharmacological options for weight management and reduction of obesity-related comorbidities, a dynamic that has redirected investment flows toward cardiometabolic programs across the biotech and pharma space in the United States and globally. Against this backdrop, Amgen’s efforts to build a pipeline that reaches beyond its legacy oncology and inflammation franchises toward cardiometabolic opportunities, including obesity, are central to its positioning in the competition for long-term growth within the US-listed large-cap biotech peer group.

Conclusion

With its shares trading roughly in line with the broader US market on 05/28/2026, Amgen remains a key S&P 500 biotechnology name watched closely by investors for both capital return and pipeline progress. The company’s efforts to broaden its presence in fast-growing treatment areas such as obesity fit into wider industry trends that are reshaping growth expectations for large-cap pharma and biotech in the United States and Europe. How Amgen executes on its clinical and regulatory milestones in this environment will continue to influence market sentiment around the stock in the months ahead.

Disclaimer: This article does not constitute investment advice. The comprehensive scope of this informative article was made possible through the use of a.i.. Stocks are volatile financial instruments.